Managed Access Programs for INC424, Ruxolitinib

Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg

NCT02742324 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

NCT01243944 ·Status: COMPLETED ·Phase: PHASE3

Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

NCT05722912 ·Status: APPROVED_FOR_MARKETING

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

NCT03144687 ·Status: COMPLETED ·Phase: PHASE2

Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids

NCT03616184 ·Status: COMPLETED ·Phase: PHASE2

Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)

NCT03674047 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.

NCT02966353 ·Status: COMPLETED ·Phase: PHASE2

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

NCT02962388 ·Status: TERMINATED ·Phase: PHASE2/PHASE3

Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

NCT06160791 ·Status: RECRUITING ·Phase: PHASE2

Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease

NCT06462469 ·Status: RECRUITING ·Phase: PHASE4

Treatment of SARS Caused by COVID-19 With Ruxolitinib

NCT04334044 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome

NCT02400463 ·Status: COMPLETED ·Phase: PHASE2

A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis

NCT06619522 ·Status: WITHDRAWN ·Phase: PHASE2

Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV

NCT05870475 ·Status: RECRUITING ·Phase: PHASE2

Ruxolitinib In GvHD

NCT02396628 ·Status: TERMINATED ·Phase: PHASE2

Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)

NCT05762640 ·Status: RECRUITING ·Phase: PHASE2

Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.

NCT02038036 ·Status: COMPLETED ·Phase: PHASE3

Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection

NCT04355793 ·Status: NO_LONGER_AVAILABLE

Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement

NCT05127421 ·Status: COMPLETED ·Phase: PHASE2

Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis

NCT00275613 ·Status: COMPLETED ·Phase: PHASE1

Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

NCT01632904 ·Status: COMPLETED ·Phase: PHASE3

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

NCT04629508 ·Status: COMPLETED ·Phase: PHASE2

Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis

NCT06951971 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

NCT00934544 ·Status: COMPLETED ·Phase: PHASE3

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

NCT03801434 ·Status: RECRUITING ·Phase: PHASE2